Prellis is dedicated to building tissues to eliminate the organ transplant waitlist.

Our mission is to use novel tissue engineering technology to advance human health.

Human tissue engineering is a complex problem. Why will Prellis succeed?


The advent of bioprinting was an exciting moment for the emerging field of tissue engineering. For the first time, cells could be extruded into different shapes and patterns with extreme accuracy and higher resolution than ever before. However, it quickly became apparent that extrusion printing would not build large transplantable organs or tissues.

At the core of the technology was an engineering problem: No bioprinting technology had the speed and the resolution necessary to build biomimetic tissues below a 100 micrometer feature size.

Capillaries, 10-20 microns in diameter, are the blood vessels where oxygen and nutrient exchange is facilitated in every living tissue. Without capillary perfusion, tissues quickly begin to die.

Prellis has solved this engineering problem by using ultra-fast laser printing to create bioprinted feature sizes and shapes that match the fine vasculature of tissues and organs.

By generating freeform biocompatible, biodegradable, nutrient and oxygen permeable scaffolds living vascularized tissues can be created in the laboratory setting.





What differentiates the EXIS™ antibody discovery platform?


The EXIS™ (Externalized human Immune System) platform uses human Lymph Node Organoids (LNOs) to replicate the human immune system in vitro. When an LNO is ‘challenged’ with a vaccine-like cocktail, Prellis is able to obtain fully human, class-switched antibody libraries of up to 100,000 antigen-specific antibodies in as little as 20 days. Prellis has obtained low nanomolar to picomolar affinity antibody libraries against 14 targets and is currently moving several human antibodies into IND enabling studies.

Contact us
if you are interested in rapid antibody discovery.





prellis-white-icon-01.png
prellis-white-icon-01.png

How is Prellis fostering the future of tissue engineering?


We believe a fundamental shift in health and medicine will occur as a direct result of human tissue and organ availability. The beginnings of this movement can be seen in the adoption of three-dimensional organoids for therapeutic screening and research. Cells in three-dimensional organoids better replicate the behavior of cells in the human body and provide more accurate therapeutic screens. Utilizing three-dimensional cell culture to screen therapeutics has the potential to save billions of dollars in R&D costs.

As we move towards this shift in health and medicine Prellis recognizes the need to engage scientists and the cell biology community as a whole.

We engage the academic community by supporting a research partner program where we significantly discount access to our vascular tissue scaffolds.
In addition, we host monthly Tissue Engineering Journal Clubs that feature presentations of cutting edge research from top tissue engineering scientists from around the world.





Human tissue engineering is a complex problem. Why will Prellis succeed?


The advent of bioprinting was an exciting moment for the emerging field of tissue engineering. For the first time, cells could be extruded into different shapes and patterns with extreme accuracy and higher resolution than ever before. However, it quickly became apparent that extrusion printing would not build large transplantable organs or tissues.

At the core of the technology was an engineering problem: No bioprinting technology had the speed and the resolution necessary to build biomimetic tissues below a 100 micrometer feature size.

Capillaries, 10-20 microns in diameter, are the blood vessels where oxygen and nutrient exchange is facilitated in every living tissue. Without capillary perfusion, tissues quickly begin to die.

Prellis has solved this engineering problem by using ultra-fast laser printing to create bioprinted feature sizes and shapes that match the fine vasculature of tissues and organs.

By generating freeform biocompatible, biodegradable, nutrient and oxygen permeable scaffolds living vascularized tissues can be created in the laboratory setting.





What differentiates the EXIS™ antibody discovery platform?


The EXIS™ (Externalized human Immune System) platform uses human Lymph Node Organoids (LNOs) to replicate the human immune system in vitro. When an LNO is ‘challenged’ with a vaccine-like cocktail, Prellis is able to obtain fully human, class-switched antibody libraries of up to 100,000 antigen-specific antibodies in as little as 20 days. Prellis has obtained low nanomolar to picomolar affinity antibody libraries against 14 targets and is currently moving several human antibodies into IND enabling studies.

Contact us
if you are interested in rapid antibody discovery.





prellis-white-icon-01.png

What differentiates the EXIS™ antibody discovery platform?


The EXIS™ (Externalized human Immune System) platform uses human Lymph Node Organoids (LNOs) to replicate the human immune system in vitro. When an LNO is ‘challenged’ with a vaccine-like cocktail, Prellis is able to obtain fully human, class-switched antibody libraries of up to 100,000 antigen-specific antibodies in as little as 20 days. Prellis has obtained low nanomolar to picomolar affinity antibody libraries against 14 targets and is currently moving several human antibodies into IND enabling studies.

Contact us
if you are interested in rapid antibody discovery.





prellis-white-icon-01.png
prellis-white-icon-01.png
prellis-white-icon-01.png

How is Prellis fostering the future of tissue engineering?


We believe a fundamental shift in health and medicine will occur as a direct result of human tissue and organ availability. The beginnings of this movement can be seen in the adoption of three-dimensional organoids for therapeutic screening and research. Cells in three-dimensional organoids better replicate the behavior of cells in the human body and provide more accurate therapeutic screens. Utilizing three-dimensional cell culture to screen therapeutics has the potential to save billions of dollars in R&D costs.

As we move towards this shift in health and medicine Prellis recognizes the need to engage scientists and the cell biology community as a whole.

We engage the academic community by supporting a research partner program where we significantly discount access to our vascular tissue scaffolds.
In addition, we host monthly Tissue Engineering Journal Clubs that feature presentations of cutting edge research from top tissue engineering scientists from around the world.





prellis-white-icon-01.png
_kidney_rotate-min.gif